Download PDF
Z Geburtshilfe Neonatol 2016; 220(01): 9-15
DOI: 10.1055/s-0035-1554626
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Behandlung der chronischen funktionellen Obstipation in der Schwangerschaft und Stillperiode

Treatment of Chronic Functional Constipation during Pregnancy and Lactation
K. Gharehbaghi
1   niedergelassener Facharzt, Vienna, Austria
,
D. R. Gharehbaghi
2   KA Rudolfstiftung, Gyn./Obstet., Vienna, Austria
,
F. Wierrani
2   KA Rudolfstiftung, Gyn./Obstet., Vienna, Austria
,
G. Sliutz
2   KA Rudolfstiftung, Gyn./Obstet., Vienna, Austria
› Author Affiliations
Further Information

Publication History

eingereicht 20 January 2015

angenommen nach Überarbeitung 29 April 2015

Publication Date:
11 February 2016 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Lösliche und unlösliche pflanzliche Fasern (Füll- und Quellmittel), Docusat-Natrium, Mineralöle (Schmier- und Gleitmittel), Makrogol (Polyethylenglykol, PEG), Zucker und Zuckeralkohole (osmotische Laxantien) und Antrachinone und diphenolische Laxantien (stimulierende Laxantien) gehören zu den herkömmlich in der Schwangerschaft und Stillperiode verwendeten Abführmittel. Sie scheinen kein Risiko für Teratogenität aufzuweisen und den Säugling nicht zu gefährden. Die Risikoklassifikation der US-amerikanischen Food and Drug Administration (FDA) für diese Substanzen ist eher durch das Fehlen von Daten als durch eine evidenzbasierte Studienlage beeinflusst und deshalb nicht hilfreich. Alternative Ansätze durch das American College of Gastroenterology’s Committee on FDA related matters (ACG-FDA) und das Motherisk Program sollen die Therapieentscheidung vereinfachen. Für neue Substanzen, wie Chlorid-Kanal-Aktivatoren und Prokinetika liegen keine Daten für Schwangerschaft und Stillzeit vor. Wir empfehlen als Mittel der ersten Wahl in der Schwangerschaft Makrogol und Laktulose, wobei Makrogol Vorteile, wie raschen Wirkeintritt und die wenig ausgeprägte Bildung von Flatulenzen aufweist. Erst bei Versagen dieser Therapie sollen ab dem zweiten Trimenon diphenolische Laxantien, wie Bisacodyl oder Natriumpicosulfat, verwendet werden. In der Schwangerschaft wird die Wahl des Laxans vor allem von seiner Gefahr, Tenesmen und damit Frühgeburtlichkeit auszulösen, bestimmt. Während des Stillens kann, je nach dem klischen Bild der Mutter, unter Makrogol (wegen fehlender Datenlage der Laktulose vorzuziehen), Laktulose, Bisacodyl und Natrium-picosulfat gewählt werden.

Abstract

Natural fibres (bulk-forming agents), docusate sodium (stool-softener), mineral oils (lubricant laxatives), macrogol (polyethylene glycol, PEG), sugars and sugar alcohols (osmotic laxatives) and anthraquinones and diphenolic laxatives (stimulant laxatives) seem to be safe medicaments regarding teratogenicity and lactation. The US Food and Drug Administration (FDA) risk categories for these substances taken during pragnancy and lactation are often the result of the lack of studies than of evidence-based information. So risk categories do not help in the decison-making for the right laxative. Alternative solutions such as proposals of the American College of Gastroenterology’s Committee on FDA related matters, (ACG-FDA) and the Motherisk Programme try to improve decision-making. For newer compounds such as chloride-channel-activators and procinetics no data regarding safe use in pregnancy and during breast-feeding are available as yet. We suggest the use of macrogol and lactulose as the first-line therapy in treating chronic constipation during pregnancy. Macrogol shows some advantages, such as faster onset of bowel action and fewer flatulences. If this treatment does not work or starts but then stops working, we recommend in the second and third trimenon a second-line treatment with diphenolic laxatives such as bisacodyl and and sodium picosulfate. During pregnancy the decision on the application of these laxatives is largely determined by the side-effects of tenesmus associated with preterm births. During lactation we recommend macrogol (preferable to lactulose due to the lack of data), lactulose, bisacodyl and sodium picosulfate, according to the nature of the conditions.

Schlüsselwörter

chronische funktionelle Obstipation - Schwangerschaft - Stillzeit - Behandlung

Key words

chronic functional constipation - pregnancy - lactation - treatment
 

  • Literatur

  • 1 Lembo A, Camilleri M. Chronic constipation. The N Engl J Med 2003; 349: 1360-1368
    CrossrefPubMedGoogle Scholar
  • 2 Jewell D, Young G. Interventions for treating constipation in pregnancy. Cochrane Database Syst Rev 2001; 2: CD001142
    PubMedGoogle Scholar
  • 3 Cullen G, O’Donoghue D. Constipation and pregnancy. Best Pract Res Clin Gastroenterol 2007; 21: 807-818
    PubMedGoogle Scholar
  • 4 Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491
    Google Scholar
  • 5 Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis 2006; 15: 237-241
    PubMedGoogle Scholar
  • 6 Pare P, Ferrazzi S, Thompson WG et al. An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001; 96: 3130-3137
    CrossrefPubMedGoogle Scholar
  • 7 Locke 3rd GR, Pemberton JH, Phillips SF. AGA technical review on constipation. American Gastroenterological Association. Gastroenterology 2000; 119: 1766-1778
    CrossrefPubMedGoogle Scholar
  • 8 Degen L, Dederding J-P, Bauerfeind P et al. Fakten und Mythen zur Obstipation – State of the Art. Schweiz Med Forum 2008; 8: 913-918
    PubMedGoogle Scholar
  • 9 No authors listed . Pregnancy labeling. FDA Drug Bull 1979; 9: 23-24
    PubMedGoogle Scholar
  • 10 Doering PL, Boothby LA, Cheok M. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks?. Am J Obstet Gynecol 2002; 187: 333-339
    CrossrefPubMedGoogle Scholar
  • 11 Kweder SL. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century. Birth Defects Res A Clin Mol Teratol 2008; 82: 605-609
    CrossrefPubMedGoogle Scholar
  • 12 Law R, Bozzo P, Koren G et. al. FDA pregnancy risk categories and the CPS: do they help or are they a hindrance?. Can Fam Physician 2010; 56: 239-241
    PubMedGoogle Scholar
  • 13 Tedesco FJ, DiPiro JT. Laxative use in constipation. American College of Gastroenterology’s Committee on FDA-Related Matters. Am J Gastroenterol 1985; 80: 303-309
    PubMedGoogle Scholar
  • 14 Trottier M, Erebara A, Bozzo P. Treating constipation during pregnancy. Can Fam Physician 2012; 58: 836-838
    PubMedGoogle Scholar
  • 15 Manz M, Meier R. Chronische Obstipation, Ursachen, Diagnostik und Therapie. Gastroenterologie und Ernährung 2008; 2: 29-33
    PubMedGoogle Scholar
  • 16 Voderholzer WA, Schatke W, Mühldorfer BE et al. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol 1997; 92: 95-108
    PubMedGoogle Scholar
  • 17 Tytgat GN, Heading RC, Müller-Lissner S et al. Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Aliment Pharmacol Ther 2003; 18: 291-301
    CrossrefPubMedGoogle Scholar
  • 18 Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747-2757
    CrossrefPubMedGoogle Scholar
  • 19 Nahrstedt A. Flachs, Hornklee, Widderchen und Blausäure. Cyanogenese in Schmetterlingen. Biol Unserer Zeit 1988; 18: 105-109
    CrossrefPubMedGoogle Scholar
  • 20 Tou JC, Chen J, Thompson LU. Flaxseed and its lignan precursor, secoisolariciresinol diglycoside, affect pregnancy outcome and reproductive development in rats. J Nutr 1998; 128: 1861-1868
    PubMedGoogle Scholar
  • 21 Francois CA, Connor SL, Bolewicz LC et al. Supplementing lactating women with flaxseed oil does not increase docosahexaenoic acid in their milk. Am J Clin Nutr 2003; 77: 226-233
    PubMedGoogle Scholar
  • 22 Suhonen R, Kantola I, Bjorksten F. Anaphylactic shock due to ingestion of psyllium laxative. Allergy 1983; 38: 363-365
    CrossrefPubMedGoogle Scholar
  • 23 Vaswani SK, Hamilton RG, Valentine MD et al. Psyllium laxative-induced anaphylaxis, asthma, and rhinitis. Allergy 1996; 51: 266-268
    CrossrefPubMedGoogle Scholar
  • 24 Jick H, Holmes LB, Hunter JR et al. First-trimester drug use and congenital disorders. JAMA 1981; 246: 343-346
    CrossrefPubMedGoogle Scholar
  • 25 Hawley PH, Byeon JJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med 2008; 11: 575-581
    CrossrefPubMedGoogle Scholar
  • 26 McRorie JW, Daggy BP, Morel JG et al. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther 1998; 12: 491-497
    CrossrefPubMedGoogle Scholar
  • 27 Tarumi Y, Wilson MP, Szafran O et al. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. J Pain Symptom Manage 2013; 45: 2-13
    CrossrefPubMedGoogle Scholar
  • 28 Sharif F, Crushell E, O’Driscoll K et al. Liquid paraffin: a reappraisal of its role in the treatment of constipation. Arch Dis Child 2001; 85: 121-124
    CrossrefPubMedGoogle Scholar
  • 29 Gal-Ezer S, Shaoul R. The safety of mineral oil in the treatment of constipation—a lesson from prolonged overdose. Clin Pediatr (Phila) 2006; 45: 856-858
    CrossrefPubMedGoogle Scholar
  • 30 Aselton P, Jick H, Milunsky A et al. First-trimester drug use and congenital disorders. Obstet Gynecol 1985; 65: 451-455
    PubMedGoogle Scholar
  • 31 Schindler AM. Isolated neonatal hypomagnesaemia associated with maternal overuse of stool softener. Lancet 1984; 2: 822
    PubMedGoogle Scholar
  • 32 Carulli N, Salvioli GF, Manenti F. Absorption of lactulose in man. Digestion 1972; 6: 139-145
    CrossrefPubMedGoogle Scholar
  • 33 DiPiro JT, Michael KA, Clark BA et al. Absorption of polyethylene glycol after administration of a PEG-electrolyte lavage solution. Clin Pharmacol 1986; 5: 153-155
    PubMedGoogle Scholar
  • 34 Attar A, Lemann A, Ferguson A et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999; 44: 226-230
    CrossrefPubMedGoogle Scholar
  • 35 Christie AH, Culbert P, Guest J. Economic impact of low dose polyethylene glycol 3350 plus electrolytes compared with lactulose in the management of idiopathic constipation in the UK. Pharmacoeconomics 2002; 20: 49-60
    CrossrefPubMedGoogle Scholar
  • 36 Hardcastle JD, Wilkins JL. The action of sennosides and related compounds on human colon and rectum. Gut 1970; 11: 1038-1042
    CrossrefPubMedGoogle Scholar
  • 37 Hervé S, Savoye G, Behbahani A et al. Results of 24-h manometric recording of colonic motor activity with endoluminal instillation of bisacodyl in patients with severe chronic slow transit constipation. Neurogastroenterol Motil 2004; 16: 397-402
    CrossrefPubMedGoogle Scholar
  • 38 Müller-Lissner et al. Hrsg Interdisziplinäre Gastroenterologie. 1. Aufl Berlin, Heidelberg: Springer-Verlag; 1989: 45-47
    Google Scholar
  • 39 Tunaru S, Althoff TF, Nüsing RM et al. Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors. Proc Natl Acad Sci USA 2012; 109: 9179-9184
    CrossrefPubMedGoogle Scholar
  • 40 Watson WC, Gordon Jr RS, Karmen A et al. The absorption and excretion of castor oil in man. J Pharm Pharmacol 1963; 15: 183-188
    CrossrefPubMedGoogle Scholar
  • 41 Acs N, Bánhidy F, Puhó EH et al. Senna treatment in pregnant women and congenital abnormalities in their offspring – a population-based case-control study. Reprod Toxicol 2009; 28: 100-104
    CrossrefPubMedGoogle Scholar
  • 42 Krumbiegel G, Schulz HU. Rhein and aloe-emodin kinetics from senna laxatives in man. Pharmacology 1993; 47: 120-124
    CrossrefPubMedGoogle Scholar
  • 43 Cameron BD, Phillips MW, Fenerty CA. Milk transfer of rhein in the rhesus monkey. Pharmacology 1988; 36 (Suppl. 01) 221-225
    CrossrefPubMedGoogle Scholar
  • 44 Faber P, Strenge-Hesse A. Relevance of rhein excretion into breast milk. Pharmacology 1988; 36 (Suppl. 01) 212-220
    CrossrefPubMedGoogle Scholar
  • 45 Roth W, Beschke K. Pharmacokinetics and laxative effect of bisacodyl following administration of various dosage forms. Arzneimittelforschung 1988; 38: 570-574
    PubMedGoogle Scholar
  • 46 Flig E, Hermann TW, Zabel M. Is bisacodyl absorbed at all from suppositories in man?. Int J Pharm 2000; 196: 11-20
    CrossrefPubMedGoogle Scholar
  • 47 Friedrich C, Richter E, Trommeshauser D et al. Absence of excretion of the active moiety of bisacodyl and sodium picosulfate into human breast milk: an open-label, parallel-group, multiple-dose study in healthy lactating women. Drug Metab Pharmacokinet 2011; 26: 458-464
    CrossrefPubMedGoogle Scholar
  • 48 Jiao HY, Kim DH, Ki JS et al. Effects of lubiprostone on pacemaker activity of interstitial cells of cajal from the mouse colon. Korean J Physiol Pharmacol 2014; 18: 341-346
    CrossrefPubMedGoogle Scholar
  • 49 Ke M, Tack J, Quigley EM et al. Effect of Prucalopride in the Treatment of Chronic Constipation in Asian and Non-Asian Women: A Pooled Analysis of 4 Randomized, Placebo-controlled Studies. J Neurogastroenterol Motil 2014; 20: 458-468
    CrossrefPubMedGoogle Scholar
  • 50 Love BL, Johnson A, Smith LS. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome. Am J Health Syst Pharm 2014; 71: 1081-1091
    CrossrefPubMedGoogle Scholar
  • 51 Schaefer C et al. Hrsg Arzneimittel in Schwangerschaft und Stillzeit. 8. Aufl München: Urban&Fischer/Elsevier; 2012: 98-100
    Google Scholar
  • 52 Spielmann H et al. Hrsg Taschenbuch der Arzneimittelverordnung in Schwangerschaft und Stillperiode. 3. Aufl Stuttgart, New York: Gustav Fischer Verlag; 1990: 164-167
    Google Scholar
  • 53 Marteau P, Cuillerier E, Meance S et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 2002; 16: 587-593
    CrossrefPubMedGoogle Scholar
  • 54 Müller-Lissner SA, Kamm MA, Scarpignato C et al. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100: 232-242
    CrossrefPubMedGoogle Scholar
  • 55 Müller-Lissner SA, Kaatz V, Brandt W et al. The perceived effect of various foods and beverages on stool consistency. Eur J Gastroenterol Hepatol 2005; 17: 109-112
    CrossrefPubMedGoogle Scholar